Literature DB >> 16713922

Pathophysiology and treatment of stroke in sickle-cell disease: present and future.

Jeffrey A Switzer1, David C Hess, Fenwick T Nichols, Robert J Adams.   

Abstract

Sickle-cell anaemia is the most common cause of stroke in children, and stroke is one of the most devastating complications of sickle-cell disease. Overt strokes are typically due to large-artery vasculopathy affecting the intracranial internal carotid arteries and proximal middle cerebral arteries, whereas silent strokes typically occur in the territory of penetrating arteries. The sickled red blood cell can contribute to the pathogenesis of stroke via abnormal adherence to the vascular endothelium and by haemolysis, which results in endothelial cell activation, a hypercoaguable state, and alterations in vasomotor tone. Red-blood-cell transfusion, the most common preventive measure for stroke in sickle-cell disease, is associated with iron overload in chronic disease. Therefore, interventions directed towards the potential mechanisms that promote vasculopathy and occlusion in sickle-cell anaemia should be investigated. Here we review the epidemiology, clinical spectrum, and pathophysiology of stroke in sickle-cell disease to identify potential therapeutic targets.

Entities:  

Mesh:

Year:  2006        PMID: 16713922     DOI: 10.1016/S1474-4422(06)70469-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  69 in total

1.  Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II.

Authors:  Miguel R Abboud; Eunsil Yim; Khaled M Musallam; Robert J Adams
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

Review 2.  Hemoglobin research and the origins of molecular medicine.

Authors:  Alan N Schechter
Journal:  Blood       Date:  2008-11-15       Impact factor: 22.113

3.  Large-Vessel Vasculopathy in Children With Sickle Cell Disease: A Magnetic Resonance Imaging Study of Infarct Topography and Focal Atrophy.

Authors:  Kristin P Guilliams; Melanie E Fields; Dustin K Ragan; Yasheng Chen; Cihat Eldeniz; Monica L Hulbert; Michael M Binkley; James N Rhodes; Joshua S Shimony; Robert C McKinstry; Katie D Vo; Hongyu An; Jin-Moo Lee; Andria L Ford
Journal:  Pediatr Neurol       Date:  2016-12-07       Impact factor: 3.372

4.  Sickle Cell Anemia Mediates Carotid Artery Expansive Remodeling That Can Be Prevented by Inhibition of JNK (c-Jun N-Terminal Kinase).

Authors:  Hannah Song; Philip M Keegan; Suhaas Anbazhakan; Christian P Rivera; Yundi Feng; Victor O Omojola; Alexus A Clark; Shuangyi Cai; Jada Selma; Rudolph L Gleason; Edward A Botchwey; Yunlong Huo; Wenchang Tan; Manu O Platt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-12       Impact factor: 8.311

5.  Tonsilectomy in sickle cell diseases.

Authors:  Mehmet Rami Helvaci; Cumali Gokce; Ramazan Davran; Can Acipayam; Seckin Akkucuk; Mustafa Ugur
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  Lower Transcranial Doppler Flow Velocities in Sickle Cell Anemia Patients on Hydroxyurea: Myth or Fact.

Authors:  Sawsan M Moeen; Ahmad F Thabet; Hosam A Hasan; Medhat A Saleh
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-08       Impact factor: 0.900

Review 7.  The role of genetics in stroke.

Authors:  John Francis; Senthil Raghunathan; Pradeep Khanna
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

8.  Use of a flow-diverting stent for ruptured dissecting aneurysm treatment in a patient with sickle cell disease.

Authors:  A A Dmytriw; J L Martinez; T Marotta; W Montanera; M Cusimano; A Bharatha
Journal:  Interv Neuroradiol       Date:  2015-12-10       Impact factor: 1.610

9.  Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia.

Authors:  Brigitte Bader-Meunier; Suzanne Verlhac; Monique Elmaleh-Bergès; Ghislaine Ithier; Fatiha Sellami; Sonia Faid; Florence Missud; Rolande Ducrocq; Corinne Alberti; Isabelle Zaccaria; Andre Baruchel; Malika Benkerrou
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

10.  Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.

Authors:  Nm Wiles; J Howard
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.